Ubiquitin crosstalk connecting cellular processes

Reproduced from Cell Division, 2006, 1: 21.
Ubiquitin crosstalk connecting cellular processes

Tom Groothuis, Nico Dantuma, Jacques Neefjes and Florian Salomons

The polypeptide ubiquitin is used in many processes as different as endocytosis, multivesicular body formation, and regulation of gene transcription. Conjugation of a single ubiquitin moiety is typically used in these processes. A polymer of ubiquitin moieties is required for tagging proteins for proteasomal degradation. Besides its role in protein degradation, ubiquitin is also engaged as mono- or polymer in intracellular signalling and DNA repair. Since free ubiquitin is present in limiting amounts in cells, changes in the demands for ubiquitin in any of these processes is likely to indirectly affect other ubiquitin modifications. For example, proteotoxic stress strongly increases poly-ubiquitylated proteins at the cost of mono-ubiquitylated histones resulting in chromatin remodelling and altered transcription. Here we discuss the interconnection between ubiquitin-dependent processes and speculate on the functional significance of the ubiquitin equilibrium as a signalling route translating cellular stress into molecular responses.

Background

Ubiquitin is a small polypeptide (76 amino acids) used in many essential cellular processes. Ubiquitin is abundantly expressed in eukaryotes and can be found in all cell types and tissues with up to 108 copies per cell (1). Processes as different as endocytosis, signal transduction, DNA repair, transcription and chromatin remodelling require ubiquitin for proper functioning (reviewed in (2-6); Figure 1). Biochemical studies suggest that a polymer of four or more ubiquitin moieties is required to label protein substrates for recognition by proteasomes (7, 8). Ubiquitin is post-translational conjugated to protein substrates through an isopeptide bond between the C-terminal glycine residue of ubiquitin and the α-amino group of a lysine residue or sometimes the α-amino group of a target protein. The conjugated ubiquitin can be a substrate for further ubiquitylation through one of its seven lysine residues leading to the formation of a poly-ubiquitin chain. Single ubiquitin and poly-ubiquitin conjugates can be recognized by various proteins containing ubiquitin binding domains (UBDs). These UBDs act similar as, for example, SH2 and SH3 domains that bind their targets dependent on phosphorylation of specific target residues. These post-translational modifications are a general mechanism for regulating protein interactions (9). A large number of different UBDs have been identified in unrelated proteins underscoring the complexity and versatility of ubiquitin modifications and ubiquitin-dependent interactions.

Ubiquitin contains seven lysine residues, all of which can be used to form poly-ubiquitin chains (10). Poly-ubiquitin chains linked through lysine-48 are most common and usually target substrate proteins for proteolysis. Other ubiquitin modifications, like poly-ubiquitylation through lysine-6 and lysine-63 are used for processes like DNA repair, endocytosis, and ribosomal protein synthesis (11-15). Mono-ubiquitylation is involved in endocytosis, multivesicular body formation and chromatin remodelling (16). As a major constituent of chromatin, histones are subjected to several post-translational modifications including ubiquitylation (17, 18). Ubiquitylation of histones affect transcriptional activity and chromatin remodelling (4, 19) and has recently been reported to be involved in DNA repair mechanisms as well (20-22).

A cascade of different classes of enzymes is required for identification and ubiquitylation of proteins (reviewed in (23, 24)). The first step in ubiquitylation is performed by the E1 ubiquitin-activating enzyme, which activates ubiquitin by formation of a thiol-ester bond between a cysteine residue of E1 and the carboxyl terminus of ubiquitin (25). The activated ubiquitin molecule is subsequently passed on to one of the different E2 ubiquitin conjugating enzymes, which also establishes a thiol-ester linkage with ubiquitin. Substrate proteins are recognized by a specific E3 ubiquitin ligase, which, in combination with E2 enzymes, ubiquitylate the substrate (26). Combinations of about twenty human E2 conjugat-

Abbreviations: DUBs, deubiquitylation enzymes; uH2A, ubiquitylated H2A; UPS, ubiquitin proteasome system.
ing enzymes with several hundreds of distinct E3 ubiquitin ligases enlarge the variety and specificity in recognizing and ubiquitylating target proteins. Similar to most post-translational signalling modifications, ubiquitin modifications are dynamic. Ubiquitin can be removed from substrates by a heterogeneous family of specific deubiquitylation enzymes (DUBs) (27). DUBs are proteases that catalyze the cleavage between the C-terminal glycine-76 of ubiquitin and the substrate. DUBs may thus counteract specific processes by removing mono-ubiquitin or poly-ubiquitin from various substrates like histones, proteasome substrates and other proteins. For example, the 19S lid of the proteasome contains a DUB (Rpn11) for the removal of poly-ubiquitin from proteasome substrates prior to proteolysis (28, 29). In addition to deubiquitylation activities, DUBs are involved in processing newly synthesized, inactive ubiquitin precursors. Thus DUBs generate all free ubiquitin molecules, and are essential for the progression of the ubiquitin cycle and the (re)generation of non-conjugated, free ubiquitin, which can be used for new ubiquitylation reactions. Here we discuss the ubiquitin homeostasis and its link to various cellular processes.

**Different pools of ubiquitin**

Several groups have described the existence of various forms of ubiquitin in eukaryotic cells, including free ubiquitin molecules, mono- and poly-ubiquitylated proteins (30-34). These pools are not static and ubiquitin cycles dynamically between these pools mediated by ubiquitylation and deubiquitylation enzymes (35, 36). The dynamics of the different ubiquitin pools could be visualized in living cells using a GFP-ubiquitin (GFP-Ub) fusion construct (37). Although this construct is about 4-fold larger than unmodified ubiquitin, it still reflected in many aspects the behaviour and localization of the endogenous protein in mono-ubiquitin modification and use in poly-ubiquitin chains for degradation (37, 38). The majority of ubiquitin is present in (large) conjugates while only a small fraction is free. A major pool of ubiquitin is conjugated to histone

---

**Figure 1. Ubiquitin: forms and functions.** Free ubiquitin molecules are present in both the nucleus and the cytosol; the protein is small enough for passive diffusion through the nuclear pore between the two compartments. Ubiquitin conjugation to target proteins plays a central role in many processes of the cell. The best-known function of ubiquitin is its involvement in protein degradation via poly-ubiquitylation in the nucleus and cytoplasm. Mono-ubiquitylation of proteins has various functions depending on the target protein; it can vary from involvement in endocytosis at the plasma membrane, to DNA repair in the nucleus.
To monitor the amount of free ubiquitin in living cells the nuclear pore was used as a molecular sieve in a FLIP (Fluorescence Loss In Photobleaching) protocol wherein the GFP fluorescence in either the complete nucleus or cytosol was bleached and the effect of GFP-Ub fluorescence in the other compartment was measured. The rationale behind this approach is that proteins up to approximately 50 kDa can passively diffuse through the nuclear pore, whereas larger species (like conjugated ubiquitin) are excluded (39). The FLIP experiment revealed different pools of GFP-Ub in the cytosol as well as the nucleus. A small fraction of GFP-Ub rapidly diffused from the non-bleached into the bleached compartment, representing the free pool of unconjugated GFP-Ub. Slowly other GFP-Ub entered the bleached compartment that may have resulted from generation of free GFP-Ub by release from substrate proteins like histones and proteasome substrates by DUBs. Similar results were obtained with a photoactivatable form of GFP-Ub where a region in the nucleus was activated and fluorescence accumulated slowly in the cytosol in time. These observations indicate that during physiological conditions only a small portion of ubiquitin is in the monomeric form. Using these approaches, three distinct ubiquitin pools could be distinguished in the cell: a small fraction of free monomeric ubiquitin; a major fraction of ubiquitylated proteins and mono-ubiquitylated histones. Smaller amounts of ubiquitin are used for processes like endocytosis and multivesicular body formation and therefore not easily detected by live cell imaging where only the major fractions of ubiquitin are distinguishable.

**Ubiquitin homeostasis**

Given the availability of a small pool of free ubiquitin, free ubiquitin has to be replenished continuously by DUBs. This ubiquitin cycle is essential to supply ubiquitin to substrates in a multitude of nuclear and cytosolic processes (Figure 2). But what happens when the ubiquitin equilibrium is disturbed? Inhibition of the proteasome results in accumulation of poly-ubiquitylated proteins. This is a reflection of proteotoxic stress since identical effects on poly-ubiquitin were observed following cell exposure to thermal stress conditions. Under these conditions, heat-labile proteins denature and provide the cell with an overload of proteasomal substrates. After a heat shock, the quantity of poly-ubiquitylated proteins increased dramatically. Since free ubiquitin is present in only in limiting amounts and neo-synthesis cannot compensate the acute needs for ubiquitin, this implies that ubiquitin molecules have to come from other sources to accommodate the increase in poly-ubiquitylated species. Accordingly several studies have shown that, following proteotoxic stress by proteasome inhibition, a redistribution of ubiquitin from the nucleus to the cytosol was observed in parallel with deubiquitylation of histones (37, 40, 41).

In principle, histone deubiquitylation could be the result of enhanced deubiquitylation activity following proteotoxic stress. This was assayed using photo-activated GFP-Ub in a protocol where the fate (i.e. the off-rate) of ubiquitin fluorescence was followed in one half of the nucleus. Proteotoxic stress did not affect the off-rate of fluorescent (photoactivated) GFP-Ub from histones indicating the DUBs were not activated by proteotoxic stress (37). Antibody microinjection experiments supported the idea

---

**Figure 2. The ubiquitin cycle.** Free ubiquitin plays a central role in the biochemistry of the cell; all processes that consume ubiquitin ultimately have to derive it from freely available ubiquitin. Because the amount of free ubiquitin is relatively small, processes that consume large amounts of ubiquitin will indirectly influence other cellular processes that depend on ubiquitin.
that histone deubiquitylation was the result of an altered equilibrium in the ubiquitin cycle (37). Proteotoxic stress results in an increased requirement for free ubiquitin for incorporation in poly-ubiquitylated substrates at the cost of mono-ubiquitylated histones. We speculate that through the limited pool of ubiquitin enhanced poly-ubiquitylation following proteotoxic stress is sensed by the nucleus by affecting the histone-ubiquitin status and thus the transcriptome.

Coupling cellular processes by the ubiquitin cycle

Ubiquitylation of histones is one of the major (and largest) modifications in chromatin. This modification is in mammalian cells mainly found on the core histone H2A. Approximately 5-15% of histone H2A is ubiquitylated, and this is associated with condensed DNA and gene silencing (42-44). H2B ubiquitylation is essential for the sliding activity of RNA polymerase II and regulates transcription (45). Deubiquitylation of histones during proteotoxic stress conditions could have serious consequences for gene transcription/silencing and chromatin arrangement. Effects on transcription (via ubiquitylated histones) are thus a predicted response to proteotoxic-mediated effects on the ubiquitin cycle (40, 41). In addition, ubiquitylation of histones is involved in the regulation of other post-transcriptional histone modifications like acetylation and methylation (4). Although histone ubiquitylation is a prerequisite for these modifications, they do not follow the same kinetics. Ubiquitin modified histones turn over every 2-3 hours (37) whereas acetylation and methylation modifications are much more stable. Changes in the ubiquitin equilibrium are expected to influence these modifications translating in effects on transcription regulation and chromatin remodelling. These findings may point towards a ubiquitin-dependent regulation mechanism based on a delicate ubiquitin homeostasis. Consequently, different cellular processes can influence each other through the availability of the rate-limiting pool of free ubiquitin. This limited pool of free ubiquitin can be of functional significance to couple proteasomal activity to chromatin remodelling and in fact act as a novel signal transduction pathway, going from stress to signalling to the nucleus by affecting ubiquitin-histone modifications. Histone ubiquitylation is also important for other processes like DNA replication, repair and recombination. Often specific histones (like H2A, H3 and H4 for nucleotide excision repair) are targeted by ubiquitylation (20-22). The key factor in the ubiquitin cycle is the existence of a limited pool of free ubiquitin, which couples the use of ubiquitin for poly-ubiquitin to (swift) effects on histone ubiquitylation. As a result, transcription, DNA repair and replication may all be affected by proteotoxic stress conditions.

Conclusions and relevance

Regulated protein turnover by the ubiquitin-proteasome system (UPS) is essential for the survival of eukaryotic cells. This process is required for various cellular processes such as cell cycle control, signalling pathways, transcription and protein quality control. Alterations in the UPS are correlated with a variety of human pathologies, like cancer, immunological disorders, inflammation and neurodegenerative diseases (46). The exact role of the UPS in the pathophysiology of these diseases however, remains poorly understood. Numerous studies suggest that inhibition of the proteasome may be efficient in the treatment in cancer and inflammation (reviewed in (47, 48)). It is well established that many cancer cells are sensitive to proteasomal inhibitors, which often induce growth arrest and killing. Proteasome inhibitors will prevent the degradation of the regulator proteins resulting in cell cycle arrest and apoptosis. However, a disturbed ubiquitin homeostasis may contribute to cell death in proteasome inhibitor-treated cells as well. The pool of free ubiquitin can be depleted through capture in poly-ubiquitylated proteasomal substrates so that other ubiquitin-dependent processes are negatively affected. In addition, histone deubiquitylation may suffice to induce growth arrest.

Many neurological disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease are caused by an accumulation of aberrant proteins leading to the formation of protein aggregates, inclusions and plaques. It is not completely clear why the UPS is failing to clear these aberrant proteins. For polyglutamine diseases like Huntington's disease it has been demonstrated that the UPS is unable to clear inclusions (49-51), and that proteasomes cannot degrade aggregated polyglutamine proteins (52) and polyglutamine peptides (53). In some disorders, mutations in proteins of the UPS are implicated (54). In addition to the accumulation of aberrant proteins many other abnormalities such as impaired axonal transport (55, 56) and altered transcription regulation (57-60) are associated with these diseases (reviewed in (61)). Although these alterations in axonal transport and transcription regulation can be explained by interference of mutations in disease-related proteins, the pathogenic mechanisms leading to neuronal death and the involvement of protein aggregates are still largely unknown. Intriguingly, the processes that are affected in these
disorders have at least one factor in common; they all require ubiquitin. In a number of disorders the accumulated proteins are ubiquitylated, while protein aggregates are also enriched in proteasomes. The question arises whether the sensitive ubiquitin equilibrium in these disorders is disturbed as a consequence of capture of poly-ubiquitylated proteins and/or inactive proteasomes in aggregates. A disturbed ubiquitin homeostasis might also contribute to alterations in, at first glance, unrelated cellular processes in neurological disorders. It is tempting to speculate that accumulation of aberrant proteins in these disorders disrupts the sensitive ubiquitin equilibrium, by trapping a significant fraction of ubiquitin and/or rendering proteasomes inactive in inclusion bodies and aggregates. As a consequence other processes requiring the availability of ubiquitin may be negatively influenced.

The flux of free ubiquitin between different cellular processes could be a passive mechanism in which unconjugated ubiquitin diffuses intracellularly until it is utilized in ubiquitylation processes. However, a recent publication suggest that active factors could actually be involved in channelling ubiquitin from one ubiquitin-dependent process to another with temporally a higher priority (62). It has been proposed that the DUB Doa1 helps to control DNA damage responses by releasing ubiquitin from proteasomal degradation into mechanisms involved in chromatin remodelling and DNA repair (62).

Ubiquitin seems more then just a signaling molecule involved in the regulation of various distinct processes in eukaryotic cells. The dynamic behaviour of ubiquitin modifications creates an equilibrium, which allows crosstalk between different cellular processes that may allow cells to translate cellular stress to molecular responses by affecting the transcriptome.

ACKNOWLEDGEMENTS
The Dantuma lab is supported by the Swedish Research Council, the Swedish Cancer Society, the HighQ foundation, the Nordic Center of Excellence ‘Neurodegeneration’ and the Karolinska Institutet. FAS is supported by the Marie Curie Research Training Network (MRTN-CT-2004-512585). TAMG is supported by a grant from the Dutch Cancer Society (KWF) (NKB 2004-3078).

COMPETING INTERESTS
The authors declare that they have no competing interests.

AUTHORS CONTRIBUTIONS
FAS and TAMG conceived the manuscript. JN and NPD revised the manuscript. All authors approved the final version.

REFERENCES
1. Yewdell JW: Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001, 11:294-297.
2. Haglund K, Dikic I: Ubiquitylation and cell signaling. EMBO J 2005, 24:3353-3359.
3. Hicke L, Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003, 19:141-172.
4. Zhang Y: Transcriptional regulation by histone ubiquitination and deubiquitination. Genes Dev 2003, 17:2733-2740.
5. Huang TT, D’Andrea AD: Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol 2006, 7:323-334.
6. Dhananjayan SC, Ismail A, Nawaz Z: Ubiquitin and control of transcription. Essays Biochem 2005, 41:69-80.
7. Pickart CM: Ubiquitin in chains. Trends Biochem Sci 2000, 25:544-548.
8. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM: Recognition of the polyubiquitin proteolytic signal. EMBO J 2000, 19:94-102.
9. Seet BT, Dikic I, Zhou MM, Pawson T: Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 2006, 7:473-483.
10. Peng J, Schwartz D, Elias JE, Thoreen CC, Cheng D, Marsischky G, Roelof H, Finley D, Gygi SP: A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 2003, 21:921-926.
11. Spence J, Gali RR, Dittmar G, Sherman F, Karin M, Finley D: Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000, 102:67-76.
12. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorokin A: Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 2006, 21:737-748.
13. Duncan LM, Piper S, Dodd RB, Saville MK, Sanderson CM, Luzio JP, Lehner PJ: Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules. EMBO J 2006, 25:1635-1645.
14. Galan JM, Hagenauer-Tsapis R: Ubiquitin lys63 is involved in ubiquitination of a yeast plasma membrane protein. EMBO J 1997, 16:5847-5854.
15. Hofmann RM, Pickart CM: Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 1999, 96:645-653.
16. Hicke L: Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001, 2:195-201.
17. Khorasanizadeh S: The nucleosome: from genomic organization to genomic regulation. Cell 2004, 116:259-272.
18. Jenuwein T, Allis CD: Translating the histone code. Science 2001, 293:1074-1080.
19. Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, Kao CF, Pillus L, Shilatifard A, Osley MA, Berger SL: Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 2003, 17:2648-2663.
20. Bergink S, Salomons FA, Hoogstraten D, Groothuis TA, de Waard H, Wu J, Yuan L, Citterio E, Houtsmuller AB, Neefjes J et al: DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev 2006, 20:1343-1352.
21. Kapetanaki MG, Guerrero-Santoro J, Bisi DC, Hsieh CL, Rapic-Otrin V, Levine AS: The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. Proc Natl Acad Sci U S A 2006, 103:2588-2593.
22. Wang H, Zhai L, Xu J, Joo HY, Jackson S, Erdjument-Bromage H, Tempst P, Xiong Y, Zhang Y: Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell 2006, 22:383-394.
23. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998, 67:425-479.
24. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70:503-533.
25. Haas AL, Rose IA: The mechanism of ubiquitin activating enzyme. A kinetic and equilibrium analysis. J Biol Chem 1982, 257:10329-10337.
26. Hochstrasser M: Ubiquitin-dependent protein degradation. Annu Rev Genet 1996, 30:405-439.
27. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R: A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
28. Verma R, Aravind L, Oania R, McDonald WH, Yates JR, 3rd, Koonin EV, Deshaies RJ: Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002, 298:611-615.
29. Yao T, Cohen RE: A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 2002, 419:403-407.
30. Wilkinson KD: Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000, 11:141-148.
31. Ciechanover A, Heller H, Elias S, Haas AL, Hershko A: ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci U S A 1980, 77:1365-1368.
32. Busch H, Goldknopf IL: Ubiquitin - protein conjugates. Mol Cell Biochem 1981, 40:173-187.
33. Haas AL, Bright PM: The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates. J Biol Chem 1985, 260:12464-12473.
34. Weissman AM: Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001, 2:169-178.
35. Haas AL, Bright PM: The dynamics of ubiquitin pools within cultured human lung fibroblasts. J Biol Chem 1987, 262:345-351.
36. Hanna J, Leggett DS, Finley D: Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol 2003, 23:9251-9261.
37. Dantuma NP, Groothuis TA, Salomons FA, Neefjes J: A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J Cell Biol 2006, 173:19-26.
38. Qian SB, Ott DE, Schubert U, Bennink JR, Yewdell JW: Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo. J Biol Chem 2002, 277:38818-38826.
39. Talcott B, Moore MS: Getting across the nuclear pore complex. Trends Cell Biol 1999, 9:312-318.
40. Carlson N, Rogers S, Rechsteiner M: Microinjection of ubiquitin: changes in protein degradation in HeLa cells subjected to heat-shock. J Cell Biol 1987, 104:547-555.
41. Mimnaugh EG, Chen HY, Davie JR, Celis JE, Neckers L: Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry 1997, 36:14418-14429.
42. Levinger L, Varshavsky A: Selective arrangement of ubiquitinated and D1 protein-containing nucleosomes within the Drosophila genome. Cell 1982, 28:375-385.
dal M, Tempst P, Jones RS, Zhang Y: Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004, 431:873-878.
45. Pavri R, Zhu B, Li G, Trojer P, Mandal S, Shilatifard A, Reinberg D: Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 2006, 125:703-717.
46. Schwartz AL, Ciechanover A: The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999, 50:57-74.
47. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC: Proteasome inhibitors as therapeutics. Essays Biochem 2005, 41:205-218.
48. Nalepa G, Rolfe M, Harper JW: Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006, 5:596-613.
49. Bence NF, Sampat RM, Kopito RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
50. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI: Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 2004, 23:4307-4318.
51. Diaz-Hernandez M, Valera AG, Moran MA, Gomez-Ramos P, Alvarez-Castelao B, Castano JG, Hernandez F, Lucas JJ: Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J Neurochem 2006, 19:1-12.
52. Verhoef LG, Lindsten K, Masucci MG, Dantuma NP: Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 2002, 11:2689-2700.
53. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL: Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004, 14:95-104.
54. Ciechanover A, Brundin P: The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
55. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J: Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 2003, 23:4499-4508.
56. Szepenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, Young M, Faber PW, MacDonald ME, McPhaul MJ et al: Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003, 40:41-52.
57. Mattson MP, Meffert MK: Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006, 13:852-860.
58. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D: Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease. Science 2002, 296:2238-2243.
59. Obrietan K, Hoyt KR: CRE-mediated transcription is increased in Huntington’s disease transgenic mice. J Neurosci 2004, 24:791-796.
60. Sugars KL, Brown R, Cook LJ, Swartz J, Rubinstein DC: Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington’s disease that contributes to polyglutamine pathogenesis. J Biol Chem 2004, 279:4988-4999.
61. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA: Molecular pathways to neurodegeneration. Nat Med 2004, 10:52-9.
62. Lis ET, Romesberg FE: Role of Doa1 in the Saccharomyces cerevisiae DNA damage response. Mol Cell Biol 2006, 26:4122-4133.